IntegraFin Holdings plc (LON:IHP – Get Free Report) insider Jonathan Gunby purchased 41 shares of the business’s stock in a transaction on Monday, September 23rd. The shares were acquired at an average cost of GBX 360 ($4.82) per share, for a total transaction of £147.60 ($197.64).
Jonathan Gunby also recently made the following trade(s):
- On Monday, July 22nd, Jonathan Gunby acquired 41 shares of IntegraFin stock. The shares were bought at an average price of GBX 372 ($4.98) per share, for a total transaction of £152.52 ($204.23).
IntegraFin Stock Performance
IHP stock traded down GBX 8 ($0.11) during mid-day trading on Tuesday, hitting GBX 364.50 ($4.88). 327,438 shares of the company were exchanged, compared to its average volume of 408,822. IntegraFin Holdings plc has a 1-year low of GBX 208.73 ($2.79) and a 1-year high of GBX 395 ($5.29). The stock has a market capitalization of £1.21 billion, a PE ratio of 2,268.75, a price-to-earnings-growth ratio of 3.14 and a beta of 1.15. The business has a 50 day simple moving average of GBX 374.01 and a 200-day simple moving average of GBX 333.85. The company has a current ratio of 8.80, a quick ratio of 0.01 and a debt-to-equity ratio of 1.73.
Analyst Ratings Changes
View Our Latest Stock Analysis on IntegraFin
About IntegraFin
IntegraFin Holdings plc, together with its subsidiaries, provides an investment platform for UK financial advisers and their clients. It operates through Investment administration services, Insurance and life assurance business, and Adviser back-office technology segments. The company operates Transact, a wrap platform that enable advisers to consolidate their clients investments using tax efficient wrappers and provide range of investment choice; and Time4Advice (T4A), an adviser practice management solution.
Featured Articles
- Five stocks we like better than IntegraFin
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Stock Market Upgrades: What Are They?
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- The Significance of Brokerage Rankings in Stock Selection
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for IntegraFin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntegraFin and related companies with MarketBeat.com's FREE daily email newsletter.